Windtree Therapeutics (OTC: WINT) discloses President and COO resignation

Rhea-AI Filing Summary

Windtree Therapeutics, Inc. reports a leadership change as Eric L. Curtis resigned from his roles as President and Chief Operating Officer, effective immediately on January 5, 2026. The company states that Jed Latkin continues to serve as President and Chief Executive Officer, and he signed the report on behalf of the company.

Positive

• None.

Negative

• Immediate resignation of President and COO: Eric L. Curtis resigned effective January 5, 2026, creating near-term leadership and operational transition risk.

Insights

Corporate governance analyst

Windtree reports the immediate resignation of its President and COO.

Windtree Therapeutics disclosed that Eric L. Curtis resigned as President and Chief Operating Officer effective January 5, 2026. These are senior operational and leadership roles, so the change may affect how day-to-day activities and strategic initiatives are managed.

The filing does not provide reasons for the resignation or details on succession plans for the President and COO positions. Jed Latkin is identified as President and Chief Executive Officer, indicating he already holds a central leadership role.

Future disclosures in company filings may clarify how the responsibilities previously held by the departing executive are reassigned and whether any further leadership changes occur.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

false 0000946486 0000946486 2026-01-05 2026-01-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2026

Windtree Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39290	94-3171943
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2600 Kelly Road, Suite 100, Warrington, Pennsylvania	18976
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (215) 488-9300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		WINT		OTCID

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 5, 2026, Eric L. Curtis resigned as President and Chief Operating Officer of Windtree Therapeutics, Inc., effective immediately.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Windtree Therapeutics, Inc.
By:	/s/ Jed Latkin
Name:	Jed Latkin
Title:	President and Chief Executive Officer

Date: January 7, 2026

FAQ

What leadership change did Windtree Therapeutics (WINT) disclose?

Windtree Therapeutics reported that Eric L. Curtis resigned as President and Chief Operating Officer, effective immediately on January 5, 2026.

When did the Windtree Therapeutics President and COO resignation become effective?

The resignation of Eric L. Curtis as President and Chief Operating Officer became effective immediately on January 5, 2026.

Does Windtree Therapeutics still have a President and CEO after this change?

Yes. The filing shows that Jed Latkin serves as President and Chief Executive Officer of Windtree Therapeutics and signed the report in that capacity.

Did Windtree Therapeutics explain why Eric L. Curtis resigned?

The disclosure states that Eric L. Curtis resigned as President and Chief Operating Officer effective January 5, 2026, but does not provide a reason in the text shown.

Which SEC item did Windtree use to report the executive resignation?

Windtree used Item 5.02, covering departures of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements.